DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG reports results
26-Apr-2019 / 06:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Media Release, April 26, 2019
BB Biotech AG reports results
In accordance with regulations on ad hoc publicity, BB Biotech AG is releasing the following information about its results of the interim financial statements as of March 31, 2019.
Based on consolidated results, BB Biotech AG reports for the first quarter a profit of CHF 890 mn (profit of CHF 28 mn in the corresponding period of the previous year) was incurred. As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.
Since beginning of the year, BB Biotech AG's share price increased 24.2% in CHF and 25.4% in EUR.
The interim report as of March 31, 2019 will be published on April 26, 2019 at 7 am.
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
26-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone:
+41 52 624 08 45
E-mail:
info@bbbiotech.com
Internet:
www.bbbiotech.ch
ISIN:
CH0038389992
WKN:
A0NFN3
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.